ISPOR Europe 2024 Home
  • About
    • News Center
  • Award Winners
  • Program
    • Program
    • Student Program
    • Learning Formats
    • Plenary Sessions
    • Posters
    • Program Committee
    • Digital Conference Pass
  • Exhibits & Sponsorship
    • Sponsor List
    • Media Partners
    • Exhibitor Directory
  • Photo Gallery
large-circle

ISPOR Europe 2024

17 - 20 November

  • Home
  • Events
  • Past Conferences
  • ISPOR Europe 2024
  • Program
  • Plenary Sessions
  • Session

  • Budget Impact Analysis of the Introduction of Tofacitinib for Treatment of Patients With Moderate to Severe Rheumatoid Arthritis, in Patients Who Have an Inadequate Response to csDMARDs and Are Refractory to bDMARDs in Algeria

    Nov 18, 2024, 16:00 PM
  • «
  • 2261
  • 2262
  • 2263
  • 2264
  • 2265
  • 2266
  • 2267
  • 2268 (current)
  • 2269
  • 2270
  • »
Quick Links
  • About
  • Media Center
  • Exhibits & Sponsorships
  • Contact Us
Policies & Legal
  • AI Policy
  • Antitrust Compliance
  • Code of Ethics
  • Cookie Policy
  • Diversity Policy
  • Funding Statement
  • Legal Disclaimer
  • Privacy Policy
  • Terms and Conditions

Subscribe

Join ISPOR

ISPOR–The Professional Society for
Health Economics and Outcomes Research

Copyright © 2018 ISPOR. All rights reserved.

International Society for Pharmacoeconomics and Outcomes Research, Inc

Website Design & Development by Matrix Group